At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGEM Cullinan Therapeutics
Market Closed 06-18 16:00:00 EDT
15.03
+0.59
+4.09%
盘后15.40
+0.37+2.46%
19:57 EDT
High15.56Low14.34Vol3.12M
Open14.80D1 Closing14.44Amplitude8.45%
Mkt Cap923.61MTradable Cap646.61MTotal Shares61.45M
T/O46.98MT/O Rate7.25%Tradable Shares43.02M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cullinan Therapeutics shareholders elect two Class III directors at annual meeting
Reuters  ·  06-17
Cullinan Therapeutics shareholders elect two Class III directors at annual meeting
Cullinan Therapeutics Price Target Maintained With a $37.00/Share by Wedbush
Dow Jones  ·  06-11
Cullinan Therapeutics Price Target Maintained With a $37.00/Share by Wedbush
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-11
Wall Street Analysts Are Bullish on Top Healthcare Picks
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
Reuters  ·  06-11
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
Cullinan Therapeutics price target raised to $46 from $33 at Clear Street
TIPRANKS  ·  06-11
Cullinan Therapeutics price target raised to $46 from $33 at Clear Street
BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner
Reuters  ·  06-11
BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner
Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)
TIPRANKS  ·  06-11
Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)
BUZZ-Cullinan rises as early-stage data show remission in autoimmune disease drugs
Reuters  ·  06-10
BUZZ-Cullinan rises as early-stage data show remission in autoimmune disease drugs
Cullinan Therapeutics releases Immunology Day presentation
Reuters  ·  06-10
Cullinan Therapeutics releases Immunology Day presentation
Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps
MT Newswires Live  ·  06-10
Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
TIPRANKS  ·  06-10
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
Cullinan Therapeutics reports CLN-978, velinotamig data
TIPRANKS  ·  06-10
Cullinan Therapeutics reports CLN-978, velinotamig data
Cullinan shares Phase 1 data showing CLN-978 induces remission in difficult-to-treat rheumatoid arthritis patients
Reuters  ·  06-10
Cullinan shares Phase 1 data showing CLN-978 induces remission in difficult-to-treat rheumatoid arthritis patients
Cullinan: Sees Additional Multi-Dose Data for Cln-978 in Ra Next Quarter and in Sle in Q4, Additional Data for Velinotamig Before End of Year
THOMSON REUTERS  ·  06-10
Cullinan: Sees Additional Multi-Dose Data for Cln-978 in Ra Next Quarter and in Sle in Q4, Additional Data for Velinotamig Before End of Year
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting Cd19 and Bcma in Autoimmune Diseases
THOMSON REUTERS  ·  06-10
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting Cd19 and Bcma in Autoimmune Diseases
Cullinan Therapeutics Inc: Cln-978 (Cd19 Tce) Eular Data Demonstrated Potential for Immune Reset, Including Remissions, in Both Sle and Ra
THOMSON REUTERS  ·  06-10
Cullinan Therapeutics Inc: Cln-978 (Cd19 Tce) Eular Data Demonstrated Potential for Immune Reset, Including Remissions, in Both Sle and Ra
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
GlobeNewswire  ·  06-10
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
TIPRANKS  ·  06-08
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)
TIPRANKS  ·  06-08
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)
Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug
Dow Jones  ·  06-08
Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug

Introduction

Company Name.
Cullinan Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Issue price:
--